大剂量静脉注射免疫球蛋白作为新型冠状病毒肺炎病情恶化患者的一种治疗选择
High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019.
作者信息
Cao Wei, Liu Xiaosheng, Bai Tao, Fan Hongwei, Hong Ke, Song Hui, Han Yang, Lin Ling, Ruan Lianguo, Li Taisheng
机构信息
Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Tsinghua-Peking Center for Life Sciences, School of Medicine, Tsinghua University, Beijing, China.
出版信息
Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102. doi: 10.1093/ofid/ofaa102. eCollection 2020 Mar.
The outbreak of coronavirus disease 2019 (COVID-19) has spread rapidly in China. Until now, no definite effective treatment has been identified. We reported on 3 patients with severe COVID-19 who received high-dose intravenous immunoglobulin (IVIg) with satisfactory recovery. Based on these observations, randomized studies of high-dose IVIg should be considered in deteriorating patients infected with COVID-19.
2019年冠状病毒病（COVID-19）疫情在中国迅速蔓延。截至目前，尚未确定明确有效的治疗方法。我们报告了3例重症COVID-19患者接受大剂量静脉注射免疫球蛋白（IVIg）治疗后恢复良好的情况。基于这些观察结果，对于病情恶化的COVID-19感染患者，应考虑进行大剂量IVIg的随机研究。
Zotero 插件